prof.dr. (Carin) C.A. Uyl-de Groot

Publications (179)

• Article (157)

  • Scholarly Publication (148)

    • S. de Groot, W.K. Redekop, M.M. Versteegh, S. Sleijfer, E. Oosterwijk, L.A.L.M. Kiemeney & C.A. de Uyl-de Groot (2018). Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma. Quality of Life Research. doi: 10.1371/journal.pone.0177364
    • L.E.M. Oosten, M. Chamuleau, W.F. Thielen, L.C. de Wreede, C. Siemes, J.K. Doorduijn, O.S. Smeekes, M. Kersten, L. Hardi, J.W. Baars, A.M.P. Demandt, W. Stevens, G.W. Nijland, C.A. de Uyl-de Groot, P.M. Kluin, D. de Jong & H. Veelken (2018). Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens. Annals of Hematology, 97 (2), 255-266.
    • H.M. Westgeest, C.A. de Uyl-de Groot, R.J.A. van Moorselaar, R. de Wit, A.C.M. van den Bergh, J.L.L.M. Coenen, H.P. Beerlage, M.P. Hendriks, M. Bos, P. van den Berg, A. van de Wouw, T. Spermon, M.O. Boerma, M.M. Geenen, L.W. Tick, M.B. Polee, H. Bloemendal, I. Cordia, F.P.J. Peters, A.I. de Vos, J. van den van den Bosch, A.J.M. Van den Eertwegh & W. Gerritsen (2017). Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry. European Urology. doi: 10.1016/j.euf.2016.09.008[go to publisher's site]
    • H.Y. Tan, M.G. Franken, H.M. Blommestein, C.A. Uyl - de Groot & P. Sonneveld (2017). Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma. Journal of Clinical Oncology, 35 (12), 1312-+. doi: 10.1200/jco.2016.71.1663
    • H.M. Blommestein, C.A. de Uyl-de Groot & S. Zweegman (2017). De econoom en de hematoloog: kosten, effecten en verantwoorde toegang tot zorg. Nederlands Tijdschrift voor Hematologie, 14 (6), 273-281.
    • N. van der Linden, M.L. Bongers, V. Coupe, E.F. Smit, H.J.M. Groen, A. Welling, F. Schramel & C.A. Uyl - de Groot (2017). Treatment Patterns and Differences in Survival of Non-Small Cell Lung Cancer Patients Between Academic and Non-Academic Hospitals in the Netherlands. Clinical Lung Cancer, 18 (5), E341-E347. doi: 10.1016/j.cllc.2015.11.011
    • M.L. Bongers, D. De Ruysscher, C. Oberije, P. Lambin, C.A. Uyl - de Groot, J. Belderbos & V. Coupe (2017). MODEL-BASED COST-EFFECTIVENESS OF CONVENTIONAL AND INNOVATIVE CHEMO-RADIATION IN LUNG CANCER. International Journal of Technology Assessment in Health Care, 33 (6), 681-690. doi: 10.1017/s0266462317000939
    • A. Jochems, M.G. Schouwenburg, B. Leeneman, M.G. Franken, A.J.M. Van den Eertwegh, J. Haanen, H. Gelderblom, C.A. de Uyl-de Groot, M. Aarts, F. van den Berkmortel, W.A.M. Blokx, M.C. Cardous-Ubbink, G. Groenewegen, J. de Groot, G.A.P. Hospers, E. Kapiteijn, R.H. Koornstra, W.H. Kruit, M. Louwman, D. Piersma, R.S. van Rijn, A. ten Tije, G. Vreugdenhil, M.W.J.M. Wouters & J.J.M. van der Hoeven (2017). Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands. European Journal of Cancer, 72, 156-165. doi: 10.1016/j.ejca.2016.11.021
    • S. de Groot, H.M. Blommestein, W.K. Redekop, S. Sleijfer, L. Kiemeney, E. Oosterwijk & C.A. de Uyl-de Groot (2017). Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments. PLoS One (print), 12 (5):e0177364. doi: 10.1371/journal.pone.0177364
    • A.G. Dinmohamed, P.C. Huijgens, M. Brink, E.F.M. Posthuma, C.A. de Uyl-de Groot, N.M.A. Blijlevens, J. Cornelissen & O. Visser (2017). Het hemato-oncologieregister van de Nederlanse Kankerregistratie: verleden, heden en toekomst. Nederlands Tijdschrift voor Hematologie, 14 (2), 55-63.
    • C.H.Y. van Beurden-Tan, M.G. Franken, H.M. Blommestein, C.A. de Uyl-de Groot & P. Sonneveld (2017). Reply to X. Armoiry et al. Journal of Clinical Oncology, 35 (25), 2976. doi: https://doi.org/10.1200/JCO.2017.73.7569
    • A. Ansaripour, C.A. de Uyl-de Groot, M. Foroozanfar, S. Rahimimoghadam & W.K. Redekop (2016). Which is more important for doctors in a middle-income country, a national guideline or the medical literature? An adherence survey of trastuzumab use for breast cancer in Iran. Journal of Cancer Policy, 9, 8-13. doi: http://dx.doi.org/10.1016/j.jcpo.2016.05.005[go to publisher's site]
    • H.M. Blommestein, P.C. Huijgens & C.A. de Uyl-de Groot (2016). De toegevoegde waarde van gegevens uit de dagelijkse praktijk. Nederlands Tijdschrift voor Hematologie, 13 (5), 206-208.
    • S. de Groot, W.K. Redekop, S. Sleijfer, E. Oosterwijk, A. Bex, L.A.L.M. Kiemeney & C.A. de Uyl-de Groot (2016). Survival in patients with primary metastatic renal cell carcinoma treated with sunitinib with or without previous cytoreductive nephrectomy: Results from a population-based registry. Urology, 95, 121-127. doi: http://dx.doi.org/10.1016/j.urology.2016.04.042[go to publisher's site]
    • W.F. Thielen, H.M. Blommestein & C.A. de Uyl-de Groot (2016). Using appropriate methods in cost-effectiveness analyses: the case of allogeneic hematopoietic cell transplantation in sickle cell disease. Biology of Blood and Marrow Transplantation, 22 (11), 2109-2110. doi: 10.1016/j.bbmt.2016.08.022[go to publisher's site]
    • A. van Dongen - Leunis, W.K. Redekop & C.A. Uyl - de Groot (2016). Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30. Value in Health, 19 (6), 834-843. doi: 10.1016/j.jval.2016.05.008[go to publisher's site]
    • D. Malone, N.S. Berg, K. Claxton, L.P. Jr. Garrison, M. Ijzerman, K. Marsh, P.J. Neumann, M. Sculpher, A. Towse, C.A. Uyl - de Groot & M.C. Weinstein (2016). International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework. Journal of Clinical Oncology, 34 (24), 2936-+. doi: 10.1200/jco.2015.64.4328
    • S. de Groot, N. van der Linden, M.G. Franken, H.M. Blommestein, B. Leeneman, E.M. van Rooijen, J.J.M. van der Hoeven, M. Wouters, H.M. Westgeest & C.A. de Uyl-de Groot (2016). Balancing the optimal and the feasible: A practical guide for setting up patient registries for the collection of real-world data for health care decision making based on Dutch experiences. Value in Health. doi: 10.1016/j.jval.2016.02.007[go to publisher's site]
    • R. Maan, R. Zaim, A.J.P. van der Meer, J. Feld, H. Wedemeyer, J. Dufour, F. Lammert, M.P. Manns, S. Zeuzem, B. Hansen, H.L.A. Janssen, B.J. Veldt, R.J. de Knegt & C.A. Uyl - de Groot (2016). Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis. Journal of Gastroenterology and Hepatology, 31 (11), 1851-1859. doi: 10.1111/jgh.13373
    • M.D. Franken, E.M. van Rooijen, C.A. Uyl - de Groot, M. van Oijen & M. Koopman (2016). Cost-effectiveness in colorectal cancer: challenges on quality and comparability. Colorectal Cancer, 5 (1), 21-31. doi: 10.2217/crc.15.33
    • H.M. Blommestein, S. de Groot, M. Aarts, P. Vemer, R. de Vries, A.F.M. Abeelen, E.F.M. Posthuma & C.A. de Uyl-de Groot (2016). Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands. Leukemia Research, 50, 37-45. doi: 10.1016/j.leukres.2016.09.005[go to publisher's site]
    • S. de Groot, S. Sleijfer, W.K. Redekop, E. Oosterwijk, J. Haanen, L.A.L.M. Kiemeney & C.A. de Uyl-de Groot (2016). Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry. Bmc Cancer, 16, 364. doi: http://dx.doi.org/10.1186/s12885-016-2395-x[go to publisher's site]
    • L.R. Buisman, M.P.M.H. Rutten - van Molken, D. Postmus, J.J. Luime, C.A. de Uyl-de Groot & W.K. Redekop (2016). The early bird catches the worm: early cost-effectiveness analysis of new medical tests. International Journal of Technology Assessment in Health Care, 32 (1-2), 46-53. doi: http://dx.doi.org/10.1017/S0266462316000064[go to publisher's site]
    • N. van der Linden, G.B. Flach, R. de Bree & C.A. de Uyl-de Groot (2016). Cost–utility of sentinel lymph node biopsy in cT1–T2N0 oral cancer. Oral Oncology, 53, 20-26. doi: http://dx.doi.org/http://dx.doi.org/10.1016/j.oraloncology.2015.11.011[go to publisher's site]
    • N. van der Linden, M.L. Bongers, V. Coupe, E.F. Smit, H.J.M. Groen, A. Welling, F. Schramel & C.A. de Uyl-de Groot (2016). Costs of non-small cell lung cancer in the Netherlands. Lung Cancer, 91, 79-88. doi: http://dx.doi.org/10.1016/j.lungcan.2015.10.015[go to publisher's site]
    • H.M. Blommestein, M.G. Franken & C.A. de Uyl-de Groot (2015). A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry. Pharmacoeconomics (Print). doi: http://dx.doi.org/10.1007/s40273-015-0260-4[go to publisher's site]
    • K.M. Goor, M.R. Schaafsma, P. Joosten, E.F. Posthuma, S. Wittebol, P.C. Huijgens, E.J. Mattijssen, G. Vreugdenhil, W. Peters, Z. Erjavec, P.W. Wijermans, S.M. Daenen, K.G. van der Hem, M. van Oers & C.A. de Uyl-de Groot (2015). Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study. Quality of Life Research, 24 (12), 2895-2906. doi: http://dx.doi.org/10.1007/s11136-015-1039-y[go to publisher's site]
    • N. van der Linden, E.F. Smit & C.A. de Uyl-de Groot (2015). Real-world costs of laboratory tests for non-small cell lung cancer. Clinical Chemistry and Laboratory Medicine, 53 (8), e187-e189. doi: http://dx.doi.org/10.1515/cclm-2014-1262[go to publisher's site]
    • C.A. de Uyl-de Groot, W.B.F. Brouwer, J.M. de Maeseneer & J. Verweij (2015). Primary care in cancer control: towards mature cancer care. Lancet Oncology, 16 (22), 1226-1227. doi: http://dx.doi.org/http://dx.doi.org/10.1016/S1470-2045(15)00294-6[go to publisher's site]
    • H.M. Blommestein, S.G.R. Verelst, S. de Groot, P.C. Huijgens, P. Sonneveld & C.A. de Uyl-de Groot (2015). A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model. European Journal of Haematology, 96 (2), 198-208. doi: http://dx.doi.org/10.1111/ejh.12571[go to publisher's site]
    • M.L. Bongers, V.M.H. Coupe, D. De Ruysscher, C. Oberije, P. Lambin & C.A. de Uyl-de Groot (2015). Individualized Positron Emission Tomography–Based Isotoxic Accelerated Radiation Therapy Is Cost-Effective Compared With Conventional Radiation Therapy: A Model-Based Evaluation. International Journal of Radiation Oncology Biology Physics, 91 (4), 857-865. doi: http://dx.doi.org/http://dx.doi.org/10.1016/j.ijrobp.2014.12.012[go to publisher's site]
    • J.G. Gaultney, M.G. Franken, C.A. de Uyl-de Groot, W.K. Redekop, P.C. Huijgens, B. van der Holt, H.M. Lokhorst & P. Sonneveld (2015). Experience with outcomes research into the real-world effectiveness of novel therapies in Dutch daily practice from the context of conditional reimbursement. Health Policy, 119 (2), 186-194. doi: http://dx.doi.org/http://dx.doi.org/10.1016/j.healthpol.2014.11.010[go to publisher's site]
    • M.L. Bongers, D. De Ruysscher, C. Oberije, P. Lambin, C.A. de Uyl-de Groot & V. Coupe (2015). Multistate Statistical Modeling: A Tool to Build a Lung Cancer Microsimulation Model That Includes Parameter Uncertainty and Patient Heterogeneity. Medical Decision Making, 36 (1), 86-100. doi: 10.1177/0272989X15574500[go to publisher's site]
    • N. van der Linden, J. Buter, C.P. Pescott, R.I. Lalisang, J. de Boer, A. de Graeff, C.M.L. van Herpen, R.J. Baatenburg de Jong & C.A. de Uyl-de Groot (2015). Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands. European Archives of Oto-Rhino-Laryngology, 273 (2), 455-464. doi: http://dx.doi.org/10.1007/s00405-015-3495-y[go to publisher's site]
    • L. Mohseninejad, C.W.M. van Gils, C.A. de Uyl-de Groot, E. Buskens & T.L. Feenstra (2015). Evaluation of Patient Registries Supporting Reimbursement Decisions: The Case of Oxaliplatin for Treatment of Stage III Colon Cancer. Value in Health, 18, 84-90. doi: http://dx.doi.org/10.1016/j.jval.2014.10.008[go to publisher's site]
    • C.W.M. van Gils, S. de Groot, S.S. Tan, W.K. Redekop, M. Koopman, C. Punt & C.A. de Uyl-de Groot (2015). Real-world resource use and costs of adjuvant treatment for stage III colon cancer. European Journal of Cancer Care, 24 (3), 321-332. doi: 10.1111/ecc.12154[go to publisher's site]
    • A. Leunis, W.K. Redekop, C.A. de Uyl-de Groot & B. Lowenberg (2014). Impaired health-related quality of life in acute myeloid leukemia survivors: a single-center study. European Journal of Haematology, 93 (3), 196-206. doi: http://dx.doi.org/10.1111/ejh.12324[go to publisher's site]
    • H.M. Blommestein, M.G. Franken, S.G.R. Verelst, M. van Agthoven, P.C. Huijgens & C.A. de Uyl-de Groot (2014). Access to expensive cancer drugs in Dutch daily practice: Should we be concerned? Netherlands Journal of Medicine, 72 (4), 235-241. doi: http://dx.doi.org/1765/77541[go to publisher's site]
    • N. van der Linden, C.W.M. van Gils, C.P. Pescott, J. Buter, M.R. Vergeer & C.A. de Uyl-de Groot (2014). Real-world cost-effectiveness of cetuximab in locally advanced squamous cell carcinoma of the head and neck. European Archives of Oto-Rhino-Laryngology, 272 (8), 2007-2016. doi: 10.1007/s00405-014-3106-3
    • C.A. de Uyl-de Groot, E.G.E. de Vries, J. Verweij & R. O' Sullivan (2014). Dispelling the myths around cancer care delivery: It's not all about costs. Journal of Cancer Policy, 2, 22-29. doi: http://dx.doi.org/10.1016/j.jcpo.2014.01.001[go to publisher's site]
    • H.M. Blommestein, D. Issa, M. Pompen, G. Ten Hoor, M. Hogendoorn, P. Joosten, S. Zweegman, P.C. Huijgens & C.A. de Uyl-de Groot (2014). Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study. European Journal of Haematology, 92, 398-406. doi: http://dx.doi.org/10.1111/ejh.12264[go to publisher's site]
    • B.W. Prick, J.J. Duvekot, P.E. van der Moer, N. van Gemund, P.C.M. van der Salm, A.J.G. Jansen, D.J. van Rhenen, B. Mol & C.A. de Uyl-de Groot (2014). Cost-effectiveness of red blood cell transfusion vs. non-intervention in women with acute anaemia after postpartum haemorrhage. Vox Sanguinis, 107 (4), 381-388. doi: http://dx.doi.org/10.1111/vox.12181[go to publisher's site]
    • A. Ansaripour, C.A. de Uyl-de Groot, A. Steenhoek & W.K. Redekop (2014). The Drug Reimbursement Decision-Making System in Iran. Value in Health Regional Issues, 3, 174-181. doi: http://dx.doi.org/10.1016/j.vhri.2014.04.010[go to publisher's site]
    • M.G. Franken, J.G. Gaultney, H.M. Blommestein, P.C. Huijgens, P. Sonneveld, W.K. Redekop & C.A. de Uyl-de Groot (2014). Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib? Value in Health, 17, 245-253. doi: http://dx.doi.org/10.1016/j.jval.2013.12.009[go to publisher's site]
    • P. Fennema, T.J. Heyse & C.A. de Uyl-de Groot (2014). Cost-effectiveness and clinical implications of advanced bearings in total knee arthroplasty: a long-term modeling analysis. International Journal of Technology Assessment in Health Care, 30 (2), 218-225. doi: http://dx.doi.org/10.1017/S0266462314000129[go to publisher's site]
    • B.W. Prick, A.J.G. Jansen, E.A.P. Steegers, W.C.J. Hop, M.L. Essink-Bot, C.A. de Uyl-de Groot, B.M.C. Akkerboom, M.M.A. van Alphen, K.W.M. Bloemenkamp, K.E. Boers, H. Bremer, A. Kwee, A.J. Loon, G.C.H. Metz, D. Papatsonis, J.A.M. van der Post, M.M. Porath, R.J.P. Rijnders, F.J.M.E. Roumen, H.C.J. Scheepers, D.H. Schippers, N.W.E. Schuitemaker, R.H. Stigter, M.D. Woiski, B.W.J. Mol, D.J. van Rhenen & J.J. Duvekot (2014). Transfusion policy after severe postpartum haemorrhage: a randomised non-inferiority trial. Bjog-An International Journal of Obstetrics and Gynaecology, 121 (8), 1005-1014. doi: http://dx.doi.org/10.1111/1471-0528.12531[go to publisher's site]
    • A. Leunis, W.K. Redekop, C.A.G.M. van Montfort, B. Lowenberg & C.A. de Uyl-de Groot (2013). The Development and Validation of a Decision-Analytic Model Representing the Full Disease Course of Acute Myeloid Leukemia. Pharmacoeconomics (Print). doi: http://dx.doi.org/10.1007/s40273-013-0058-1[go to publisher's site]
    • C.W.M. van Gils, S. de Groot, W.K. Redekop, M. Koopman, C.J.A. Punt & C.A. de Uyl-de Groot (2013). Real-World Cost-Effectiveness of Oxaliplatin in Stage III Colon Cancer: A Synthesis of Clinical Trial and Daily Practice Evidence. Pharmacoeconomics (Print), 31 (8), 703-718. doi: http://dx.doi.org/10.1007/s40273-013-0061-6[go to publisher's site]
    • J.G. Gaultney & C.A. de Uyl-de Groot (2013). Efficient allocation of novel agents in multiple myeloma: a work in progress. Oncologist, 18 (1), 5-7. doi: 10.1634/theoncologist.2012-0484.
    • F.J.B. Lötters, B. Lucius, H.P. Sleeboom, A. Bochove, R.C.M. Pelger, F.L. Erdkamp & C.A. de Uyl-de Groot (2013). Voorkomen van botcomplicaties bij patienten met borstkanker: een doelmatigheidsmodel. Nederlands Tijdschrift voor Oncologie, 10 (3), 109-116.
    • K.M. Goor, C.A.M. Boumans, M.R. Schaafsma, O. de Weerdt, P. Joosten, E.F.M. Posthuma, S. Wittebol, P.C. Huijgens, E.J.M. Mattijssen, G. Vreugdenhil, H. Visser, W. Peters, Z. Erjavec, P.W. Wijermans, S.M.G.J. Daenen, K.G. van der Hem, M.H.J. van Oers & C.A. de Uyl-de Groot (2013). Real-world costs of chronic lymphocytic leukaemia in the Netherlands. Leukemia Research, 38, 84-90. doi: http://dx.doi.org/10.1016/j.leukres.2013.10.029[go to publisher's site]
    • N. van der Linden, C.W.M. van Gils, C.P. Pescott, J. Buter & C.A. de Uyl-de Groot (2013). Cetuximab in locally advanced squamous cell carcinoma of the head and neck: generalizability of EMR 062202-006 trial results. European Archives of Oto-Rhino-Laryngology, 271 (6), 1673-1678. doi: http://dx.doi.org/10.1007/s00405-013-2646-2[go to publisher's site]
    • R. Crott, M.M. Versteegh & C.A. de Uyl-de Groot (2013). An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences. Quality of Life Research, 22 (5), 1045-1054. doi: 10.1007/s11136-012-0220-9.[go to publisher's site]
    • W.H. Tong, I.M. van der Sluis, C.J.M. Alleman, R. van Litsenburg, G.J.L. Kaspers, R. Pieters & C.A. de Uyl-de Groot (2013). Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy. Haematologica, 98 (5), 753-759. doi: http://dx.doi.org/10.3324/haematol.2012.073510[go to publisher's site]
    • M.G. Franken, C.W.M. van Gils, J.G. Gaultney, G. Delwel, W. Goettsch, P.C. Huijgens, A. Steenhoek, C.J.A. Punt, M. Koopman, W.K. Redekop & C.A. de Uyl-de Groot (2013). Practical feasibility of outcomes research in oncology: Lessons learned in assessing drug use and cost-effectiveness in The Netherlands. European Journal of Cancer, 49, 8-16. doi: http://dx.doi.org/10.1016/j.ejca.2012.06.010[go to publisher's site]
    • J.G. Gaultney, M.G. Franken, S.S. Tan, W.K. Redekop, P.C. Huijgens, P. Sonneveld & C.A. de Uyl-de Groot (2013). Real-world healthcare costs of relapsed/refractory multiple myeloma during the era of novel cancer agents. Journal of Clinical Pharmacy and Therapeutics, 38, 41-47. doi: 10.1111/jcpt.12020
    • A. Leunis, H.M. Blommestein, P.C. Huijgens, N.M.A. Blijlevens, M. Jongen-Lavrencic & C.A. de Uyl-de Groot (2013). The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands. Leukemia Research, 37, 245-250. doi: http://dx.doi.org/10.1016/j.leukres.2012.09.018[go to publisher's site]
    • E. Bastiaannet, C.A. Uyl - de Groot, A. Brouwers, E.J. van der Jagt, O.S. Hoekstra, W. Oyen, F. Verzijlbergen, B. van Ooijen, J.F. Thompson & H.J. Hoekstra (2012). Cost-effectiveness of Adding FDG-PET or CT to the Diagnostic Work-up of Patients With Stage III Melanoma. Annals of Surgery, 255 (4), 771-776. doi: http://dx.doi.org/10.1097/SLA.0b013e31824a5742[go to publisher's site]
    • M.M. Versteegh, A. Leunis, J.J. Luime, M. Boggild, C.A. Uyl - de Groot & E.A. Stolk (2012). Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D. Medical Decision Making, 32 (4), 554-568. doi: http://dx.doi.org/10.1177/0272989X11427761[go to publisher's site]
    • J.G. Gaultney, M.G. Franken, S.S. Tan, W.K. Redekop, P.C. Huijgens, P. Sonneveld & C.A. de Uyl-de Groot (2012). Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents. Journal of Clinical Pharmacy and Therapeutics. doi: http://dx.doi.org/10.1111/jcpt.12020
    • M.M. Versteegh, A. Leunis, C.A. de Uyl-de Groot & E.A. Stolk (2012). Condition- Specific Preference-Based Measures: Benefit or Burden? Value in Health, 15, 504-513. doi: http://dx.doi.org/10.1016/j.jval.2011.12.003
    • M.M. Versteegh, A. Leunis, J.J. Luime, M. Boggild, C.A. de Uyl-de Groot & E.A. Stolk (2012). Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D. Medical Decision Making, 32, 554-568. doi: http://dx.doi.org/10.1177/0272989X11427761
    • J.G. Gaultney, W.K. Redekop, P. Sonneveld & C.A. de Uyl-de Groot (2012). Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value. Expert Review of Anticancer Therapy, 12 (6), 839-854. doi: http://dx.doi.org/10.1586/era.12.42[go to publisher's site]
    • C.W.M. van Gils, M. Koopman, L. Mol, W.K. Redekop, C.A. de Uyl-de Groot & C.J.A. Punt (2012). Adjuvant chemotherapy in stage III colon cancer: Guideline implementation, patterns of use and outcomes in daily practice in The Netherlands. Acta Oncologica, 51, 57-64. doi: http://dx.doi.org/10.3109/0284186X.2011.633930
    • H.M. Blommestein, S.G.R. Verelst, P.C. Huijgens, N.M.A. Blijlevens, J.J. Cornelissen & C.A. de Uyl-de Groot (2012). Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study. Annals of Hematology, 91 (12), 1945-1952. doi: http://dx.doi.org/10.1007/s00277-012-1530-2[go to publisher's site]
    • H.M. Blommestein, S.G.R. Verelst, P.C. Huijgens, N.M.A. Blijlevens, J.J. Cornelissen & C.A. de Uyl-de Groot (2012). Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study. Annals of Hematology, 91, 1945-1952. doi: http://dx.doi.org/10.1007/s00277-012-1530-2
    • S.A. Baeten, R.M.P.M. Baltussen, C.A. de Uyl-de Groot, J.F.P. Bridges & L.W. Niessen (2011). Reducing Disparities in Breast Cancer Survival - The Effect of Large-Scale Screening of the Uninsured. Breast Journal, 17 (5), 548-549. doi: http://dx.doi.org/10.1111/j.1524-4741.2011.01135.x
    • J.G. Gaultney, W.K. Redekop, P. Sonneveld & C.A. de Uyl-de Groot (2011). Critical review of economic evaluations in multiple myeloma: An overview of the economic evidence and quality of the methodology. European Journal of Cancer, 47 (10), 1458-1467. doi: http://dx.doi.org/10.1016/j.ejca.2011.04.005
    • J.G. Gaultney, E. Sanhueza, J.J. Janssen, W.K. Redekop & C.A. de Uyl-de Groot (2011). Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia. Pharmacogenomics, 12 (3), 411-421. doi: http://dx.doi.org/10.2217/pgs.10.187
    • S.G.R. Verelst, F. Termorshuizen, C.A. Uyl - de Groot, M.R. Schaafsma, A.H.M. Ammerlaan, S. Wittebol, H. Sinnige, S. Zweegman, M. van Marwijk-Kooy, R. van der Griend, H.M. Lokhorst, P. Sonneveld & P.W. Wijermans (2011). Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial. Annals of Hematology, 90 (12), 1427-1439. doi: http://dx.doi.org/10.1007/s00277-011-1224-1[go to publisher's site]
    • R. van Litsenburg, C.A. de Uyl-de Groot, H. Raat, G.J.L. Kaspers & R.J.B.J. Gemke (2011). Cost-Effectiveness of Treatment of Childhood Acute Lymphoblastic Leukemia With Chemotherapy Only: The Influence of New Medication and Diagnostic Technology. Pediatric Blood & Cancer, 57 (6), 1005-1010. doi: http://dx.doi.org/10.1002/pbc.23197
    • C.A. de Uyl-de Groot, S. de Groot & A. Steenhoek (2010). The economics of improved cancer survival rates: better outcomes, higher costs. Expert review of pharmacoeconomics & outcomes research, 10 (3), 283-292. doi: http://dx.doi.org/10.1586/erp.10.27
    • S.A. Baeten, R.M.P.M. Baltussen, C.A. de Uyl-de Groot, J. Bridges & L.W. Niessen (2010). Incorporating Equity-Effeciency Interactions in Cost-Effectiveness Analysis-Three Approaches Applied to Breast Cancer Control. Value in Health, 13 (5), 573-579. doi: http://dx.doi.org/10.1111/j.1524-4733.2010.00718.x
    • C.A. de Uyl-de Groot, A. Senft, R. de Bree, R. Leemans & O.S. Hoekstra (2010). Chest CT and Whole-Body 18F-FDG PET Are Cost-Effective in Screening for Distant Metastases in Head and Neck Cancer Patients. Journal of Nuclear Medicine, 51 (2), 176-182. doi: http://dx.doi.org/10.2967/jnumed.109.067371
    • N. van der Linden, C.A. de Uyl-de Groot & P.W. Wijermans (2010). ‘Patient’s en doctor’s delay’ bij multipelmyeloom en de ziekte van Waldenström. Nederlands Tijdschrift voor Hematologie, 7 (6), 218-223.
    • S.S. Tan, C.W.M. van Gils, M.G. Franken, L. Hakkaart-van Roijen & C.A. de Uyl-de Groot (2010). The Unit Costs of Inpatient Hospital Days, Outpatient Visits and Daycare Treatments in the Fields of Oncology and Hematology. Value in Health, 13 (6), 712-719. doi: http://dx.doi.org/10.1111/j.1524-4733.2010.00740.x
    • C.A. de Uyl-de Groot, R. Stupp & M. van den Bent (2009). Cost-effectiveness of temozolomide for the threatment of newly diagnosed glioblastoma multiforme. Expert review of pharmacoeconomics & outcomes research, 9 (3), 235-241. doi: http://dx.doi.org/10.1586/erp.09.15
    • F.F.H. Rutten, C.A. de Uyl-de Groot & A.G. Vulto (2009). Innovative payment systems for medicines in Europe. EJHP Practice, 15 (3), 60-62.
    • C.A.M. Boumans, J. Janssen, P. Huijgens & C.A. de Uyl-de Groot (2009). Costs of haematological adverse events in chronic myeloid leukaemia patients: a retrospective cost analysis of the treatment of anaemia, neutropenia and thrombocytopenia in patients with chronic myeloid leukaemia. Journal of Medical Economics, 12 (2), 164-169. doi: http://dx.doi.org/10.3111/13696990903149479
    • A.C.G. van Hooren, W.B.F. Brouwer, R. de Bree, O.S. Hoekstra, C.R. Leemans & C.A. de Uyl-de Groot (2009). The cost-effectiveness of FDG-PET in selecting patients with suspicion of recurrent laryngeal carcinoma after radiotherapy for direct laryngoscopy. European Archives of Oto-Rhino-Laryngology, 266 (9), 1441-1448.
    • W. Nijdam, P.C. Levendag, I. Noever-Smit, P.I.M. Schmitz & C.A. de Uyl-de Groot (2008). Longitudinal changes in quality of life and costs in long-term survivors of tumors of the oropharynx treated with brachytherapy or surgery. Brachytherapy, 7, 343-350. doi: http://dx.doi.org/10.1016/j.brachy.2008.05.001
    • J. Lamers, R. Stupp, M.J. van den Bent, M.J. Al, T. Gorlia, J. Wasserfallen, N. Mittmann, S. Seung, R. Crott & C.A. de Uyl-de Groot (2008). Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme. Cancer, 112 (6), 1337-1344.
    • R. de Bree, R. Reith, J.J. Quak, C.A. de Uyl-de Groot, M. van Agthoven & C.R. Leemans (2007). Free radial forearm flap versus pectoralis major myocutaneous flap reconstruction of oral and oropharyngeal defects: a cost analysis. Clinical Otolaryngology, 32, 275-282. doi: http://dx.doi.org/10.1111/j.1365-2273.2007.01466.x
    • R. de Bree, L. van der Putten, O.S. Hoekstra, D.J. Kuik, C.A. de Uyl-de Groot, H. van Tinteren, C.R. Leemans & M. Boers (2007). A randomized trial of PET scanning to improve diagnostic yield of direct laryngoscopy in patients with suspicion of recurent laryngeal carcinoma after radiotherapy. Contemporary Clinical Trials, 28, 705-712. doi: http://dx.doi.org/10.1016/j.cct.2007.03.009
    • H.M. Krol, M.I. Koopman & C.A. de Uyl-de Groot (2007). A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer. Expert Opinion on Pharmacotherapy, 8, 1313-1328. doi: http://dx.doi.org/10.1517/14656566.8.9.1313
    • S.S. Tan, C.A. de Uyl-de Groot, P.C. Huijgens & W.E. Fibbe (2007). Stem cell transplantation in Europe: trends and prospects. European Journal of Cancer, 43, 2359-2365. doi: http://dx.doi.org/10.1016/j.ejca.2007.08.020
    • L.M. Lamers, C.A. de Uyl-de Groot & I. Buijt (2007). The Use of Disease-Specific Outcome Measures in Cost-Utility Analysis. Pharmacoeconomics (Print), 25 (7), 591-603. doi: http://dx.doi.org/10.2165/00019053-200725070-00005
    • W.M. Nijdam, P.C. Levendag, D. Fuller, R. Schulz, J.G.H.G. Prevost, I. Smit & C.A. de Uyl-de Groot (2007). Robotic radiosurgery vs. brachytherapy as a boost to intensity modulated radiotherapy for tonsillar fossa and soft palate tumors: the clinical and economic impact of an emerging technology. Technology Cancer Research Treatment, 6, 611-619.
    • G.J.M. Herder, H. Kramer, O.S. Hoekstra, E.F. Smit, J. Pruim, H. van Tinteren, E.F.I. Comans, P. Verboom, C.A. de Uyl-de Groot, A. Welling, M.A. Paul, M.M. Boers, P.E. Postmus, G.J. Teule & H.J.M. Groen (2006). Traditional Versus up-Front (18F) Fluorodeoxyglucose Positron Emission Tomography Staging of Non-Small-Cell Lung Cancer: A Dutch Cooperative Randomized Study. Journal of Clinical Oncology, 24 (12), 1800-1806.
    • M.T. Groot, R.M.P.M. Baltussen, C.A. de Uyl-de Groot, B.O. Anderson & G.N. Hortobagyi (2006). Costs and Health Effects of Breast Cancer Interventions in Epidemiologically Different Regions of Africa, North America and Asia. Breast Journal, 12 (1), 81-90. doi: http://dx.doi.org/10.1111/j.1075-122X.2006.00206.x
    • M.G.H. Niezen, E.A. Stolk, A. Steenhoek & C.A. de Uyl-de Groot (2006). Inequalities in oncology care: Economic consequences of high cost drugs. European Journal of Cancer, 42, 2887-2892. doi: http://dx.doi.org/10.1016/j.ejca.2006.07.009
    • C.A. de Uyl-de Groot (2006). Economic evaluation of cancer therapies: More and better studies will lead to better choices in cancer care. European Journal of Cancer, 42, 2862-2866. doi: http://dx.doi.org/10.1016/j.ejca.2006.08.008
    • M.T. Groot, P.C. Huijgens & C.A. de Uyl-de Groot (2006). Introduction of expensive pharmaceuticals in haematooncology in the Netherlands and throughout Europe. European Journal of Hospital Pharmacy Practice, 12, 30-36.
    • M. van Agthoven, HAG Heule-Dieleman, P.P.M. Knegt, J. Kaanders, R.J. Baatenburg de Jong, B. Kremer, C.R. Leemans, H.A.M. Marres, J.J. Manni, J.A. Langendijk, P.C. Levendag, R.E. Tjho-Heslinga, J.M.A. de Jong, M.F. de Boer & C.A. de Uyl-de Groot (2006). Compliance and efficiency before and after implementation of a clinical practice guideline for laryngeal carcinomas. Laryngology, 263, 729-737. doi: http://dx.doi.org/10.1007/s00405-006-0062-6
    • M.T. Groot, P.J. Lugtenburg, J. Hornberger, P.C. Huijgens & C.A. de Uyl-de Groot (2005). (MabThera) in diffuse large B-cell lymphoma in the Netherlands. European Journal of Haematology, 74, 194-202.
    • M. van Agthoven, P. Sonneveld, L.F. Verdonck & C.A. de Uyl-de Groot (2005). Cost determinants in aggressive non-Hodgkin's lymphoma. Haematologica, 90 (5), 661-671.
    • C.A. de Uyl-de Groot, J.B. Vermorken, M. Hanna, P. Verboom, M.T. Groot, G.J. Bonsel, C.J.L.M. Meijer & H.M. Pinedo (2005). Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine, 23 (17-18), 2379-2387. doi: http://dx.doi.org/10.1016/j.vaccine.2005.01.015
    • C.A. de Uyl-de Groot, J. Mcdonnell, H.J.M. Groen, D. Radice & G. Velde (2005). Cost-effectiveness of new drugs in patients with phase IIIB-IV non-small lung cancer: Results of a Markov chain model. European Journal of Hospital Pharmacy Science, 2, 37-41.
    • M.T. Groot, P.J. Lugtenburg, J. Hornberger, P.C. Huijgens & C.A. de Uyl-de Groot (2005). Cost-effectiveness of rituximab (MabThera (R)) in diffuse large B-cell lymphoma in the Netherlands. European Journal of Haematology, 74 (3), 194-202. doi: http://dx.doi.org/10.1111/j.1600-0609.2004.00368.x
    • C.A. de Uyl-de Groot, I. Buijt, I. Gloudemans, G.J. Ossenkoppele, H. van den Berg & P.C. Huijgens (2005). Health related quality of life in patients with multiple myeloma undergoing a double transplantation. European Journal of Haematology, 74 (2), 136-143. doi: http://dx.doi.org/10.1111/j.1600-0609.2004.00346.x
    • C.A. de Uyl-de Groot & G. Giaccone (2005). Health economics: can we afford an unrestricted use of new biological agents in gastrointestinal oncology? Current Opinion in Oncology, 17 (4), 392-396. doi: http://dx.doi.org/10.1097/01.cco.0000168535.25330.6a
    • M. van Agthoven, HAG Heule-Dieleman, M.F. de Boer, J. Kaanders, R.J. Baatenburg de Jong, B. Kremer, C.R. Leemans, H.A.M. Marres, J.J. Manni, J.A. Langendijk, P.C. Levendag, R.E. Tjho-Heslinga, J.M.A. de Jong, C.A. de Uyl-de Groot & P.P.M. Knegt (2005). Evaluating adherence to the Dutch guideline for diagnosis, treatment and follow-up of laryngeal carcinomas. Radiotherapy and Oncology, 74 (3), 337-344. doi: http://dx.doi.org/10.1016/j.radonc.2005.01.003
    • M. van Agthoven, M.H.H. Kramer, P. Sonneveld, K.G. van der Hem, P.C. Huijgens, P.W. Wijermans, H.C. Kluin-Nelemans, M.R. Schaafsma, D.H. Biesma, V. Mattijssen, C.A. de Uyl-de Groot & A. Hagenbeek (2005). Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma. Haematologica, 90 (10), 1422-1432.
    • C.A. de Uyl-de Groot, J. den Hartog & J.G.M. Derksen (2004). Cost-effectiveness and quality of life of granulocyte-colony stimulating factor after radical vulvectomy and bilateral inguino-femoral lymphadenectomy: results of a randomized clinical trial. Gynec Repr Biol, 114, 77-82.
    • M. van Agthoven, C. Segeren, I. Buijt, C.A. de Uyl-de Groot, B. van der Holt, H.M. Lokhorst & P. Sonneveld (2004). A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemd patients with stage II/III multiple myeloma: a prospective randomised phototherapy with autologous stem-cell rescue in a newly diagnose. European Journal of Cancer, 40, 1159-1169.
    • W.M. Nijdam, P.C. Levendag, I. Noever-Smit, C.A. de Uyl-de Groot & M. van Agthoven (2004). Cost analysis comparing brachytherapy versus surgery for primary carcinoma of the tonsillar fossa and/or soft palate. International Journal of Radiation Oncology Biology Physics, 59 (2), 488-494. doi: http://dx.doi.org/10.1016/j.ijrobp.2003.11.002
    • M. van Agthoven, S. Wittebol, L.M. Budel, C.A. de Uyl-de Groot & M.H.H. Kramer (2004). Survival of patients with aggressive non-hodgkin's lymphoma: no difference between first line teratment in a prospective randomised phase III clinical trial and first line treatment according to routine clinical practice. Nederlands Tijdschrift voor Geneeskunde, 148, 88-93.
    • M. van Agthoven, S. Wittebol, L.M. Budel, C.A. de Uyl-de Groot & M.H.H. Kramer (2004). Overleving van patienten met aggressief non-hodgkinlymfoom. Nederlands Tijdschrift voor Geneeskunde, 148, 88-93.
    • M. van Agthoven, C.A. de Uyl-de Groot, P. Sonneveld & A. Hagenbeek (2004). Economic assessment in the management of non-Hodgkin's lymphoma. Expert Opinion Pharmacotherapy, 12, 2529-2548.
    • M.T. Groot, P.C. Huijgens, C.A. de Uyl-de Groot & P. Wijermans (2004). Costs of multiple myeloma and associated skeletal-related events in the Netherlands. Expert review of pharmacoeconomics & outcomes research, 4, 565-572. doi: http://dx.doi.org/10.1586/14737167.4.5.565
    • M.T. Groot, M. van Agthoven, B. Lowenberg, R. Willemze & C.A. de Uyl-de Groot (2004). The role of cost analysis in the evaluation of the development of medical technology.The case of allogenic stem-cell transplantation. Nederlands Tijdschrift voor Geneeskunde, 148, 480-484.
    • J. Doorduyn, I. Buijt, B. van der Holt, M. van Agthoven, P. Sonneveld & C.A. de Uyl-de Groot (2004). Economic evaluation of prophylacticgranulocyte colony-stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma. Haematologica, 89 (9), 1109-1117.
    • M.T. Groot, G.J. Ossenkoppele, M.H.H. Kramer, G. van den Boom, P.C. Huijgens & C.A. de Uyl-de Groot (2003). Medicamenteuze behandeling van chronische myeloïde leukemie: een kosteneffectiviteitsanalyse van 1e en 2e lijnsbehandeling. Nederlands Tijdschrift voor Geneeskunde, 50, 1460-1465.
    • M. van Agthoven, P. Sonneveld, A. Hagenbeek & C.A. de Uyl-de Groot (2003). A review of recruitment criteria, patient characteristics and results of CHOP chemotherapy in prospective randomized phase III clinical trials for aggressive non-Hodgkin's lymphoma. Hematology Journal, 4, 399-409. doi: http://dx.doi.org/10.1038/sj.thj.6200323
    • J. Doorduyn, B. van der Holt, G.W. van Imhoff, K.G. van der Hem, M.H.H. Kramer, M.H.J. van Oers, G.J. Ossenkoppele, M.R. Schaafsma, L.F. Verdonck, G.E.G. Verhoef, M.M.C. Steijaert, I. Buijt, C.A. de Uyl-de Groot, M. van Agthoven, A.H. Mulder & P. Sonneveld (2003). CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology, 21 (16), 3041-3050.
    • M.T. Groot, C.G.G. Boeken Kruger, R.C.M. Pelger & C.A. de Uyl-de Groot (2003). Costs of prostate cancer, metastatic to the bone, in The Netherlands. European Urology, 43, 226-232. doi: http://dx.doi.org/10.1016/S0302-2838(03)00007-1
    • P. Verboom, H. van Tinteren, O.S. Hoekstra, E.F. Smit, J.H.A.M. van den Bergh, A.J.M. Schreurs, R.A.L.M. Stallaert, P.C.M. van Velthoven, E.F.I. Comans, F.W. Diepenhorst & C.A. de Uyl-de Groot (2003). Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study. European Journal of Nuclear Medicine and Molecular Imaging, 30, 1444-1449.
    • M. van Agthoven, C.A. de Uyl-de Groot, L.F. Verdonck, B. Lowenberg, A.V.M.B. Schattenberg, M. Oudshoorn, A. Hagenbeek, J.J. Cornelissen & R. Willemze (2002). Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia. Bone Marrow Transplantation, 30, 243-251. doi: http://dx.doi.org/10.1038/sj.bmt.1703641
    • M. van Agthoven, C.A. de Uyl-de Groot, W.J. Fokkens, J.P. van de Merwe & J.J. van Busschbach (2002). Cost analysis of regular and filgrastim treatment in patients with refractory chronic rhinosinusitis. Rhinology, 40, 69-74.
    • P.C. Levendag, W.M. Nijdam, M. van Agthoven & C.A. de Uyl-de Groot (2002). Chemotherapy and high-dose-rate brachytherapy in the management of advanced cancers of the nasopharynx: clinical impact of high techology - is it worth the cost? Brachytherapy, 1, 11-20. doi: http://dx.doi.org/10.1016/S1538-4721(02)00005-3
    • M. van Agthoven, L.M. Faber, C.A. de Uyl-de Groot, P. Sonneveld, L.F. Verdonck, R. Willemze, J.C. Kluin-Nelemans, B. Lowenberg & P.C. Huijgens (2002). Cost analysis of first-line CHOP (-like) chemotherapy regimens for patients with intermediate or high-grade non-Hodgkin's lymphoma. European Journal of Haematology, 69, 213-220. doi: http://dx.doi.org/10.1034/j.1600-0609.2002.02772.x
    • E. Vellenga, M. van Agthoven, A.J. Croockewit, L.F. Verdonck, P. Wijermans, M.H.J. van Oers, C. Volkers, G.W. van Imhoff, T. Kingma, C.A. de Uyl-de Groot & W.E. Fibbe (2001). Autologous peripheral blood stem cell transplantation in patients with relaps lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study. British Journal of Haematology, 114 (2), 319-326. doi: http://dx.doi.org/10.1046/j.1365-2141.2001.02926.x
    • C.A. de Uyl-de Groot, J. den Hartog, P.C. Huijgens, R. Willemze & B.M. van Ineveld (2001). Costs of diagnosis, treatment, and follow up of patients with acute myeloid leukemia in the Netherlands. Journal of Hematotherapy & Stem Cell Research, 10, 187-192. doi: http://dx.doi.org/10.1089/152581601750098499
    • M. van Agthoven, E. Vellenga, W.E. Fibbe, T. Kingma & C.A. de Uyl-de Groot (2001). Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma Hodgkin's disease: a prospective. European Journal of Cancer, 37 (14), 1781-1789. doi: http://dx.doi.org/10.1016/S0959-8049(01)00198-8
    • N. Li, M. van Agthoven, P.H.B. Willemse & C.A. de Uyl-de Groot (2001). A cost-utility analysis of several second-line chemoharapy schemes in patients with metastatic breast cancer. Anti-Cancer Drugs, 12 (6), 533-540.
    • M. van Agthoven, B.M. van Ineveld, M.F. de Boer, C.R. Leemans, P.P.M. Knegt, G.B. Snow & C.A. de Uyl-de Groot (2001). The costs of head and neck oncology, primary tumour recurrent tumours and long-term follow-up. European Journal of Cancer, 37 (17), 2204-2211. doi: http://dx.doi.org/10.1016/S0959-8049(01)00292-1
    • M. van Agthoven, W.J. Fokkens, J.P. van de Merwe, E.M. van Bolhuis, C.A. de Uyl-de Groot & J.J. van Busschbach (2001). Quality of life effects of filgrastim treatment in patients with refractory chronic rhinosinusitis. American Journal of Rhinology, 15 (4), 231-238.
    • L.M. Faber, M. van Agthoven, C.A. de Uyl-de Groot, B. Lowenberg & P.C. Huijgens (2000). Diagnostiek en behandeling van het non-Hodgkin-lymfoom in Nederland: variëteit in richtlijnen en in de praktijk. Nederlands Tijdschrift voor Geneeskunde, 144 (25), 1223-1227.
    • C.A. de Uyl-de Groot (2000). Cost-effectiveness of stem-cell transplantations in non-Hodgkin's lymphoma in the Netherlands. ONE, 1 (8), 49-52.
    • C.A. de Uyl-de Groot, S. Wait & I. Buijt (2000). Economics and health-related quality of life in antiemetic therapy: recommendations for trial design. European Journal of Cancer, 36, 1522-1535. doi: http://dx.doi.org/10.1016/S0959-8049(00)00132-5
    • C.A. de Uyl-de Groot, G.J. Ossenkoppele, I. Buijt & P.C. Huijgens (1999). Stem Cell Transplantations in Patients with Malignant Lymphoma: Costs in a Dutch University Hospital in the Period 1984-1995. Journal of Hematotherapy & Stem Cell Research, 619-625. doi: http://dx.doi.org/10.1089/152581699319786
    • C.A. de Uyl-de Groot, G.J. Ossenkoppele, I. Buijt & P.C. Huijgens (1999). Costs of Peripheral Blood Progenitor Cell Transplantation Using Whole Blood Mobilised by Filgrastim as Compared With Autologous Bone Marrow Transpantation in Non-Hodgkin's Lymphoma. Pharmacoeconomics (Print), 15 (3), 305-311. doi: http://dx.doi.org/10.2165/00019053-199915030-00009
    • C.A. de Uyl-de Groot, B. Lowenberg, E. Vellenga, S. Suciu, R. Willemze & F.F.H. Rutten (1998). Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukaemia. British Journal of Haematology, 100, 629-636.
    • J. Bonnema, A. van Wersch, A.N. van Geel, J. Pruyn, P.I.M.@. Schmitz, C.A. de Uyl-de Groot & T. Wiggers (1998). Cost of care in a randomised trial of early hospital discharge after surgery for breast cancer. European Journal of Cancer, 34 (13), 2015-2020.
    • C.A. de Uyl-de Groot & C.R. Touw (1998). Economic evaluation of cancer treatments: methodological and practical issues. Anti-Cancer Drugs, 9, 833-841.
    • I. Buijt, C.A. de Uyl-de Groot & P.C. Huijgens (1998). Costs of intensive treatment and follow-up of patients with multiple myeloma. Anti-Cancer Drugs, 9, 889-897.
    • C.A. de Uyl-de Groot, B. Lowenberg, E. Vellenga, S. Suciu, R. Willemze & F.F.H. Rutten (1998). Cost-effectiveness and quality- of- life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukaemia. British Journal of Haematology, 100, 629-636.
    • C.A. de Uyl-de Groot, E. Vellenga, E.G.E. de Vries, B. Lowenberg, G. Stoter & F.F.H. Rutten (1997). Treatment Costs and Quality of Life with Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Antineoplastic Therapy-Related Febrile Neutropenia. Pharmacoeconomics (Print), 351-360.
    • C.A. de Uyl-de Groot (1997). Farmaco-economische evaluaties gekoppeld aan klinische studies. Ziekenhuisfarmacie, 109-112.
    • C.A. de Uyl-de Groot, E. Vellenga, E.G.E. de Vries, B. Lowenberg, G.J. Stoter & F.F.H. Rutten (1997). Treatment costs and quality of life with granulocyte-macrophage colony-stimulating factor in patients with antineoplastic therapy-related febrile neutropenia: results of a randomised placebo-controlled trial. Pharmacoeconomics (Print), 12 (3), 351-360.
    • C.A. de Uyl-de Groot, P.C. Huijgens & F.F.H. Rutten (1996). Colony-Stimulating Factors and Peripheral Blood Progenitor Cell Transplantation. Pharmacoeconomics (Print), 10 (1), 23-35.
    • E. Vellenga, C.A. de Uyl-de Groot, G. Stoter, B. Lowenberg & E.G.E. de Vries (1996). Sneller herstel van leukocyten door hematopoëtische groeifactor bij patiënten met door chemotherapie veroorzaakte granulocytopenie en koorts, maar geen kortere opnameduur. Nederlands Tijdschrift voor Geneeskunde, 140 (32), 1650-1655.
    • C. Williams, D. Coyle, J. Hutton, A. Gray, T. Jefferson, G. Karlsson, K. Kesteloot, C.A. de Uyl-de Groot & S. Wait (1996). European School of Oncology Advisory Report to the Commission of the European Communities for the "Europe Against Cancer Programme" Cost-effectiveness in Cancer Care. European Journal of Cancer, 31a (9), 1410-1424.
    • L.S. Hofstra, C.A. de Uyl-de Groot & E. Vellenga (1996). Clinical role of GM-CSF in neutrophil recovery in relation to health care parameters. Medical Oncology, 177-184.
    • E. Vellenga, C.A. de Uyl-de Groot, R. de Wit, H.J. Keizer, B. Lowenberg, M.A. ten Haaft, Th.J.M. de Witte, C.A.H. Verhagen, G.J. Stoter, F.F.H. Rutten, N.H. Mulder, W.M. Smid & E.G.E. de Vries (1996). Randomized Placebo-Controlled Trial of Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Chemotherapy-Related Febrile Neutropenia. Journal of Clinical Oncology, 14 (2), 619-627.
    • C.A. de Uyl-de Groot, E. Vellenga & F.F.H. Rutten (1996). An Economic Model to Assess the Savings From a Clinical Application of Haematopoietic Growth Factors. European Journal of Cancer, 32a (1), 57-62.
    • C.A. de Uyl-de Groot, A. Hagenbeek, L.F. Verdonck, F.F.H. Rutten & B. Lowenberg (1995). Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL). Bone Marrow Transplantation, 463-470.
    • C.A. de Uyl-de Groot, S.Y. Okhuijsen, A. Hagenbeek, P.C. Huijgens, G.W. van Imhoff, B. Lowenberg, L.F. Verdonck & F.F.H. Rutten (1995). Costs of introducing autologous BMT in the treatment of lymphoma and acute leukaemia in The Netherlands. Bone Marrow Transplantation, 605-610.

  • Professional Publication (9)

    • R. de Kleijn, C. Hagen, C.A. de Uyl-de Groot, P. Pasker de Jong & P. Ter Wee (2015). PREDICTION OF CARE BURDEN OF PATIENTS UNDERGOING HAEMODIALYSIS: DEVELOPMENT OF A MEASURING TOOL. Journal of Renal care, 1-7. doi: http://dx.doi.org/10.1111/jorc.12109
    • M.P.M.H. Rutten - van Molken & C.A. de Uyl-de Groot (2012). Naar gepast gebruik van geneesmiddelen. Economisch-Statistische Berichten, 97 (4644S), 87-93. doi: niet bekend
    • P.C. Huijgens, E.F.M. Posthuma, J.W.W. Coebergh, L.V. van de Poll-Franse, C.A. de Uyl-de Groot & P. Sonneveld (2010). Een 'population based registry' voor hemato-oncologie. Nederlands Tijdschrift voor Hematologie, 7 (8), 321-324.
    • C.A. de Uyl-de Groot & A. Steenhoek (2007). Nieuwe 'dure' kankergeneesmiddelen en kosteneffectiviteitsanalyses: hoe is de stand van zaken? IKR-bulletin (Rotterdam), 31, 28-30.
    • R.R. de Bree, O.S. Hoekstra, L. van der Putten, M. Boers, C.A. de Uyl-de Groot & C.R. Leemans (2005). Recidief larynxcarcinoom na radiotherapie-PET studie: RELAPS. Nederlands Tijdschrift voor Oncologie, 2, 119.
    • M.T. Groot, N. van Overbeke, L. Annemans & C.A. de Uyl-de Groot (2002). Kostenanalyse van het medisch handelen bij gemetastaseerd colorectaal carcinoom: een vergelijking tussen 5-FU Leucovorine (LV) en UFT Leuvovorin (LV). Pharmaceutisch Weekblad, 137 (20), 714-721.
    • E. Elsinga & C.A. de Uyl-de Groot (1996). Dure geneesmiddelen in het ziekenhuis: De Taxol zaak nader belicht. ZorgVisie (Maarssen), 26 (5), 8-11.
    • F.F.H. Rutten & C.A. de Uyl-de Groot (1996). Pharmacoeconomic Evaluation in Clinical Practice. Clinical Pharmacist, 1 (1), 30-35.
    • F.F.H. Rutten & C.A. de Uyl-de Groot (1995). Economic evaluation and cancer treatment: Limits to growth. Helix. Amgen's Magazine of Biotechnology, 4 (3), 41-47.

• Report (5)

  • Scholarly Publication (1)

    • C.A. de Uyl-de Groot & D.T. Stierman (2014). Resultaten monitor overheveling TNF-alfaremmers, groeihormonen, oncologische- en andere geneesmiddelen. Rotterdam: Institute for Medical Technology Assessment / Instituut voor Beleid en Management Gezondheidszorg Erasmus Universiteit Rotterdam

  • Professional Publication (3)

    • K.M. Goor, C.A.M. Boumans, M.R. Schaafsma & C.A. de Uyl-de Groot (2011). A cost of illness and equality of life study in patients with B-cell chronic lymphocytic leukemia (CLL) in the Netherlands. (Extern rapport). Rotterdam: eigen beheer iBMG/EUR
    • M. van Agthoven, L.M. Faber & C.A. de Uyl-de Groot (2001). Diagnostiek, behandeling en follow-up van het intermediair en hooggradig Non-Hodgkin Lymfoom. Kosten van protocollaire en niet-protocollaire behandelingen. (Intern rapport, no 01.55). :
    • M. van Agthoven, M.T. Groot & C.A. de Uyl-de Groot (2001). Kosten van allogene stamceltransplantaties. (Intern rapport, no 01.57). :

  • Other Publication (1)

    • M.G. Franken, J.G. Gaultney, H.M. Blommestein, S.S. Tan, C.W.M. van Gils, P.C. Huijgens, P. Sonneveld, W.K. Redekop & C.A. de Uyl-de Groot (2012). Pilot outcomes research: effects and costs of bortezomib in relapsed or refractory multiple myeloma. (Extern rapport). Rotterdam: Erasmus Universiteit Rotterdam - GE-iMTA

• Book / Monograph / Book editorial (1)

  • M.P.M.H. Rutten - van Molken, C.A. de Uyl-de Groot & F.F.H. Rutten (2010). Een handleiding voor economische evaluatiestudies in de gezondheidszorg Tweede herziene druk. Amsterdam: Elsevier

• Part of book - Chapter (1)

  • C.A. de Uyl-de Groot (2000). Uitgangspunten en opzet van onderzoek. In M.P.M.H. Rutten- van Mölken, J.J. van Busschbach & F.F.H. Rutten (Eds.), Van kosten tot effecten (pp. 17-30). Maarssen: Elsevier gezondheidszorg

• Inaugural speech (1)

  • C.A. de Uyl-de Groot (2011). 'Dure' diagnostiek en kangergeneesmiddelen: de andere kant van de ongelijkheid II. Oratie (2011, mei 20). Rotterdam: eigen beheer iBMG/EUR

• Award (1)

  • A. Ansaripour, K. Zendehdel, N. Tadayon, F. Sadeghi, C.A. de Uyl-de Groot & W.K. Redekop (2016). Use of data-mining to perform a real world cost analysis of HER2-positive breast cancer in Iran. 19th Annual European Congress: Vienna - Austeria (2016, oktober 29 - 2016, november 2). Overig.

• Doctoral thesis (1)

  • C.A. de Uyl-de Groot (1995, september 20). Economic evaluation of cancer treatments. BMG (233 pag.) Prom./coprom.: prof.dr. F.F.H. Rutten.

• Supervised Theses (12)

  • S. de Groot. Evidence from clinical practice to support healthcare decision making, evaluation of clinical and economic outcomes of new therapies for metastatic renal cell carcinoma. EUR Prom./coprom.: prof.dr. C.A. de Uyl-de Groot, L.A.L.M. Kiemeney & dr. W.K. Redekop.
  • H.M. Blommestein (2016, april 1). The added value of real-world evidence. EUR (203 pag.) (Rotterdam: Optima grafische commuicatie) Prom./coprom.: prof.dr. C.A. de Uyl-de Groot & P.C. Huijgens.
  • A. Leunis. The cost-effectiveness of personalized medicine strategies in acute myeloid leukemia. EUR Prom./coprom.: prof.dr. C.A. de Uyl-de Groot, Prof. Dr. B. Lowenberg & dr. W.K. Redekop.
  • N. van der Linden. The use of real-world data in lung and head and neck oncology. EUR Prom./coprom.: prof.dr. C.A. de Uyl-de Groot.
  • C. Koedoot. The impact and treatment of developmental stuttering. EUR Prom./coprom.: prof.dr. C.A. de Uyl-de Groot, Prof. Dr. R.J. Baatenburg de Jong & dr. E.A. Stolk.
  • K.M. Goor. Health Technology Assessment of health care innovations in Chronic Lymphocytic Leukaemia and Glaucoma Care: The value of mixed methods research. EUR Prom./coprom.: prof.dr. C.A. de Uyl-de Groot & dr. M.A. Koopmanschap.
  • M.G. Franken (2014, december 5). Decision Making in Drug Reimbursement. EUR (266 pag.) Prom./coprom.: prof.dr. C.A. de Uyl-de Groot & A. de Boer.
  • M. Oppe (2013, mei 30). Mathematical approaches in economic evaluations. EUR (163 pag.) Prom./coprom.: prof.dr. C.A. de Uyl-de Groot & Dr. F.T. de Charro.
  • C.W.M. van Gils (2013, december 19). Real-world cost-effectiveness. EUR (214 pag.) (Rotterdam) Prom./coprom.: prof.dr. C.A. de Uyl-de Groot, C.J.A. Punt & dr. W.K. Redekop.
  • S.S. Tan (2009, november 27). Microcosting in Economic Evaluations. EUR (219 pag.) (Rotterdam: Optima Grafische Communicate) Prom./coprom.: prof.dr. C.A. de Uyl-de Groot & dr. L. Hakkaart-van Roijen.
  • M.T. Groot (2006, april 21). Economic evaluation; serving different actors n a changing environment; some examples. EUR (162 pag.) Prom./coprom.: prof.dr. F.F.H. Rutten, P.C. Huijgens & prof.dr. C.A. de Uyl-de Groot.
  • M. van Agthoven (2004, september 23). Economic evaluations in aggressive Non-Hodghkin's lymphoma. EUR (192 pag.) Prom./coprom.: prof.dr. F.F.H. Rutten, P. Sonneveld & prof.dr. C.A. de Uyl-de Groot.

Present position

Ancillary activities (5)